New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapy

Overview of attention for article published in Journal for Immunotherapy of Cancer, March 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

So far, Altmetric has seen 4 news stories from 4 outlets.

) - Cellceutix Corporation ( OTC: CTIX ) (the "Company"), a clinical stage biopharmaceutical company developing innovative…

) - Cellceutix Corporation ( OTC: CTIX ) (the "Company"), a clinical stage biopharmaceutical company developing innovative…

BEVERLY, MA--(Marketwired - August 20, 2015) - Cellceutix Corporation ( OTC: CTIX ) (the "Company"), a clinical stage…

BEVERLY MAMarketwired August 20 2015 Cellceutix Corporation OTC CTIX the "Company" a clinical stage biopharmaceutical company…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.